<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973904</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-ISS-CO214</org_study_id>
    <nct_id>NCT04973904</nct_id>
  </id_info>
  <brief_title>Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer</brief_title>
  <official_title>A Single-Arm, Multicenter, Phase II Study to Investigate Efficacy and Safety of Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Recurrent, Refractory and Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, multicenter, phase II study to investigate efficacy and safety of&#xD;
      Toripalimab combined with chemotherapy (paclitaxel and cisplatin) and Bevacizumab as&#xD;
      first-line treatment in patients with recurrent, refractory and metastatic cervical cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of therapy with&#xD;
      toripalimab andchemotherapy (paclitaxel and cisplatin) and Bevacizumab as first-line&#xD;
      treatment in patients with recurrent, refractory and metastatic cervical cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients with at least one tumor scan of complete response (CR) or partial response (PR) using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients with at least one tumor scan of complete response (CR) or partial response (PR) or stable disease (SD) using RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time from cycle 1, day 1 of treatment to disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time from cycle 1, day 1 of treatment until death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>PD-1+Paclitaxel+Cisplatin+Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W)&#xD;
Paclitaxel 175mg/m2 IV every 3 weeks (Q3W)&#xD;
Cisplatin 50mg/m2 (Q3W)&#xD;
Bevacizumab 7.5mg/kg IV every 3 weeks (Q3W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>PD-1+Paclitaxel+Cisplatin+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>PD-1+Paclitaxel+Cisplatin+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>PD-1+Paclitaxel+Cisplatin+Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>PD-1+Paclitaxel+Cisplatin+Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Cervical squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma&#xD;
             diagnosed by histopathology&#xD;
&#xD;
          -  FIGO stage IVB according to 2018 FIGO staging classification; Any FIGO stage with&#xD;
             persistent or progressed lesions after treatment; Any FIGO stage with recurrent&#xD;
             lesions and recurrent-free interval &gt; 6 month&#xD;
&#xD;
          -  Subjects has not been treated with systemic chemotherapy and is not amenable to&#xD;
             curative treatment (such as with surgery and/or radiation). Subject who previously&#xD;
             treated with cisplatin-based CCRT is allowed&#xD;
&#xD;
          -  Has measurable disease per RECIST 1.1&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          -  Written and signed informed consent.&#xD;
&#xD;
          -  Patients must have adequate function as defined:&#xD;
&#xD;
               1. ANC≥1.5*10^9/L; PLT≥100*10^9/L, Hb≥90 g/L, WBC≥3.5*10^9/L&#xD;
&#xD;
               2. Total Bilirubin (TBIL)≤1.5*Upper Limit of Normal(UNL)&#xD;
&#xD;
               3. Alanine Transaminase (ALT)and Aspartate Aminotransferase(AST)≤2.5*ULN.For liver&#xD;
                  metastasis patients, ALT and AST≤5*ULN, Alkaline phosphatase (ALP) ≤ 3 x UNL. For&#xD;
                  liver metastasis patients, Alkaline phosphatase (ALP) ≤ 5 x UNL&#xD;
&#xD;
               4. Cr≤ ULN, or creatinine clearance rate ≥60 mL/min,&#xD;
&#xD;
          -  Proteinuria ≤1+，if proteinuria≥ 1+ and 24 hours total urine protein ≤ 1.0 g&#xD;
&#xD;
          -  Patients who did not receive anticoagulant therapy: INR ≤ 1.5 × ULN. If the patient&#xD;
             receives prophylactic anticoagulant therapy, the INR ≤ 2 × ULN within 14 days before&#xD;
             the start of the study treatment and the activated partial thromboplastin time is&#xD;
             within the normal range, acceptable for enrollment&#xD;
&#xD;
          -  Has not a history of autoimmune diseases&#xD;
&#xD;
          -  Controlled hepatitis B or hepatitis C subjects are eligible to participate in the&#xD;
             study as long as they meet the following criteria: The HBV viral load must be less&#xD;
             than 2,000 IU/mL (&lt; 10000 copies/ml). Subjects have received anti-HBV therapy for 2&#xD;
             weeks before starting the study treatment and should maintain the same treatment&#xD;
             throughout the study treatment period. Subjects with positive HCV RNA should receive&#xD;
             anti-HCV therapy and liver function ≤ CTCAE Grade 1.&#xD;
&#xD;
          -  Subjects has not received corticosteroids or other immunosuppressive medications&#xD;
             within 14 days prior to the study treatment.&#xD;
&#xD;
          -  Female subjects must not be pregnant, not breastfeeding, and at least one of the&#xD;
             following conditions can be included in the study: women who do not have fertility or&#xD;
             who agree to be at least 60 days after the treatment and the last study drug&#xD;
             administration Fertility women who take contraceptive measures as required by the&#xD;
             programme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic treatment for recurrent, secondarily progressive or initially&#xD;
             metastatic disease&#xD;
&#xD;
          -  Indications for potentially curative treatment (surgery or radiation therapy)&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks before enrollment,or has not recovered&#xD;
             from the effects of radiotherapy.&#xD;
&#xD;
          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.&#xD;
             Participants with known brain metastases may participate provided that the brain&#xD;
             metastases have been previously treated with radiotherapy or surgery only and are&#xD;
             radiographically stable&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated&#xD;
             drainage (once a month or more frequently); Patients with stable symptoms for at least&#xD;
             two weeks after drainage could be enrolled&#xD;
&#xD;
          -  Patients with cirrhosis of any cause&#xD;
&#xD;
          -  Major surgery, open biopsy or major trauma were performed within 28 days before the&#xD;
             first dose of treatment&#xD;
&#xD;
          -  Gastrointestinal or other active bleeding, gastrointestinal perforation&#xD;
&#xD;
          -  History of organ fistula (such as gallbladder fistula, tracheal fistula, pancreatic&#xD;
             fistula, etc.)&#xD;
&#xD;
          -  Coagulation disorder or thromboembolic disease without standard anticoagulant therapy&#xD;
&#xD;
          -  uncontrolled hypertension, hypertensive crisis, hypertensive encephalopathy&#xD;
&#xD;
          -  Patients with severe wounds that cannot be healed, ulcers or fractures&#xD;
&#xD;
          -  Grade ≥ 3 venous thromboembolic events (VTE)&#xD;
&#xD;
          -  History of arterial thromboembolism&#xD;
&#xD;
          -  Acute intestinal obstruction in the last 6 months&#xD;
&#xD;
          -  A history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA)&#xD;
             or subarachnoid hemorrhage within six months&#xD;
&#xD;
          -  Previous use of any anti-PD-1, anti-PD-L1 / L2 antibody, anti-CTLA-4 antibody and&#xD;
             other immunotherapy and VEGF/VEGFR inhibitors (including bevacizumab)&#xD;
&#xD;
          -  Known hypersensitivity or allergy to paclitaxel, cisplatin, carboplatin, bevacizumab,&#xD;
             Toripalimab or any of their excipients.&#xD;
&#xD;
          -  Another malignant tumor is known and is currently undergoing progress or has been&#xD;
             actively treated in the past 3 years. Note: Subjects who have received skin basal cell&#xD;
             carcinoma, cutaneous squamous cell carcinoma, or carcinoma in situ (eg, breast cancer,&#xD;
             bladder cancer in situ) that may be curable may be treated.&#xD;
&#xD;
          -  Major surgery was performed within 3 weeks before enrollment or had not completely&#xD;
             recovered from the previous surgery (the definition of major surgery refers to the&#xD;
             level 3 and level 4 surgery in the administrative measures for clinical application of&#xD;
             medical technology implemented on May 1, 2009)&#xD;
&#xD;
          -  Known mental illness or substance abuse conditions can impede the ability of the&#xD;
             subject to meet research requirements&#xD;
&#xD;
          -  Poor compliance&#xD;
&#xD;
          -  Active pulmonary tuberculosis (TB), who are receiving anti-tuberculosis treatment or&#xD;
             have received anti-tuberculosis treatment within one year before the first dose of&#xD;
             treatment&#xD;
&#xD;
          -  A history of positive HIV&#xD;
&#xD;
          -  Patients with acute or chronic hepatitis B or hepatitis C infection, HBV DNA &gt; 2000 IU&#xD;
             / ml or 104 copies / ml; HCV RNA &gt; 103 copies / ml; Hepatitis B surface antigen&#xD;
             (HbsAg) and anti HCV antibody double positive.&#xD;
&#xD;
          -  Active autoimmune diseases, or have a history of autoimmune diseases or syndrome&#xD;
             requiring systemic steroid / immunosuppressant use, such as hypophysitis, pneumonia,&#xD;
             colitis, hepatitis, nephritis, hyperthyroidism, hypothyroidism, etc&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 28 days before Cycle 1, Day 1 or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study&#xD;
&#xD;
          -  Currently participating in other clinical trials&#xD;
&#xD;
          -  Serious and uncontrollable comorbidities that may affect the compliance of the&#xD;
             protocol or interfere with the results, including active opportunistic infections or&#xD;
             advanced (severe) infections, uncontrolled diabetes, cardiovascular diseases (grade&#xD;
             III or IV heart failure defined by the New York Heart Association classification),&#xD;
             cardiac conduction block &gt; secondary degree, myocardial infarction in the past 6&#xD;
             months, Unstable arrhythmia or unstable angina pectoris, cerebral infarction within 3&#xD;
             months, etc.) or pulmonary diseases (history of interstitial pneumonia, obstructive&#xD;
             pulmonary disease and symptomatic bronchospasm)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  A history of allogeneic stem cell transplantation or organ transplantation&#xD;
&#xD;
          -  Patients who were not suitable for this study due to other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Xiang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Xiang</last_name>
    <phone>010-69156068</phone>
    <email>XiangY@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Toripalimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

